1. American Cancer Society. Kidney Cancer (Adult) - Renal Cell Carcinoma 2011.

2. Motzer RJ, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.

3. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.

4. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs. placebo/interferon-α2a as first-line therapy in metstatic renal cell carcinoma. Proc ASCO 2007;25:18S(Abstract 3).

5. Inoki K, Guan K-L. Complexity of the TOR signaling network. Trends in Cell Biol 2006;16(4):206-212.

6. Hudes G, Carducci M, Tomczak, et al. Temsirolimus, interferon alpha or both for advanced renal cancer. N Engl J Med 2007;356:2271-81.

7. Kay A, Motzer R, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). Paper presented at: 2009 Genitourinary Cancers Symposium; February 26-29, 2009, Orlando, Florida.

8. Yazji S, Bukowski R, Kondagunta V, Figlin R. Final results from a phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastic clear cell renal cell carcinoma (mCCRCC). Proc ASCO 2007;25:18S (Abstract 5094).

9. Dham A, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Proc ASCO 25:18S(Abstract 5106) 2007.

10. Tamaskar I, et al. Antitumor effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma who had prior therapy with antiangiogenic agents. Proc ASCO 24:18S(Abstract 4597) 2006.

11. Escudier B, et al. Sequential use of sorfenib and sunitinib in renal cancer: retrospective analysis in 90 patients. Proc ASCO 25:18S(Abstract 5038) 2007.

12. George DJ, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. Proc ASCO 25:18S(Abstract 5035) 2007.

13. Robert C, et al. (2005) Cutaneous side effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6(7): 491-500.

14. System ENABLE™.